COGT — Cogent Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $641.57m
- $375.86m
- 37
- 17
- 38
- 21
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 22.5 | 7.87 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 54.7 | 90.1 | 75.6 | 148 | 208 |
Operating Profit | -32.2 | -82.2 | -75.6 | -148 | -208 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -31.8 | -74.8 | -72.3 | -140 | -192 |
Net Income After Taxes | -31.8 | -74.8 | -72.3 | -140 | -192 |
Net Income Before Extraordinary Items | |||||
Net Income | -31.8 | -74.8 | -72.3 | -140 | -192 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -31.8 | -179 | -72.3 | -140 | -192 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.18 | -16.5 | -1.87 | -2.38 | -2.42 |